Lee Gary K.

Chief Scientific Officer

Lee Gary K. has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Aug 25, 2026.

On the most recent filing, Lee Gary K. is listed as Chief Scientific Officer at Lyell Immunopharma, Inc. Inside the rolling window, Lee Gary K. reported no open-market purchases and 6 open-market sales totaling $72K in LYEL. The largest disclosed transaction in the window is a sale of 1,671 LYEL shares on Feb 11, 2026, worth $39K.

Companies traded

Other insiders at LYEL

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$72K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
LYELSale$23KAug 25SEC ↗
LYELSale$2KAug 11SEC ↗
LYELSale$2KJun 15SEC ↗
LYELSale$39KFeb 12SEC ↗
LYELSale$3KFeb 11SEC ↗
LYELSale$2KNov 12SEC ↗
Showing 1–6 of 6
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Lee Gary K. made?

Lee Gary K. has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.

Which companies does Lee Gary K. trade?

Lee Gary K. has filed SEC Form 4 disclosures for 1 company, including LYEL.

When was Lee Gary K.'s most recent SEC Form 4 filing?

Lee Gary K.'s most recent SEC Form 4 filing on Tracefour is dated Aug 25, 2026.

What is Lee Gary K.'s job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Lee Gary K. is listed as Chief Scientific Officer.

What is Lee Gary K.'s total buy and sell value in the current window?

Inside the rolling retention window, Lee Gary K. bought $0 and sold $72K based on SEC Form 4 filings.

What was Lee Gary K.'s largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 1,671 LYEL shares on 2026-02-11, worth $39K, per SEC Form 4 filings.